» Articles » PMID: 9697884

Mutational Analysis of the PTEN/MMAC1 Gene in Non-Hodgkin's Lymphoma

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 1998 Aug 11
PMID 9697884
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The PTEN/MMAC1 gene at 10q23.3, which has dual specific phosphatase activity, is a novel tumor suppressor gene candidate. Various kinds of tumors have mutations in this gene, including glioblastoma, endometrial carcinoma and prostate cancer. We examined 29 cases of primary non-Hodgkin's lymphoma (NHL) for mutations in the PTEN/MMAC1 gene. One case of diffuse large B cell lymphoma had an 11 bp deletion, but the remaining 28 cases showed no mutations in the genome. Two of these 28 cases showed missense mutations in the PTEN/MMAC1 transcripts, but no alterations in the genomic DNA. These mRNA missense variants are similar to PTEN/MMAC1 transcript aberrations which have been reported in patients with breast cancer. These findings suggest that alterations in the PTEN/MMAC1 gene play a role in the pathogenesis of NHL.

Citing Articles

The PTEN tumor suppressor gene and its role in lymphoma pathogenesis.

Wang X, Huang H, Young K Aging (Albany NY). 2015; 7(12):1032-49.

PMID: 26655726 PMC: 4712330. DOI: 10.18632/aging.100855.


miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.

Zou Z, Fan L, Wang L, Xu J, Zhang R, Tian T Oncotarget. 2014; 6(2):1276-85.

PMID: 25361012 PMC: 4359232. DOI: 10.18632/oncotarget.2626.


Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

Smith S, Van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A J Clin Oncol. 2010; 28(31):4740-6.

PMID: 20837940 PMC: 3020703. DOI: 10.1200/JCO.2010.29.2813.


Planarian PTEN homologs regulate stem cells and regeneration through TOR signaling.

Oviedo N, Pearson B, Levin M, Sanchez Alvarado A Dis Model Mech. 2008; 1(2-3):131-43.

PMID: 19048075 PMC: 2562200. DOI: 10.1242/dmm.000117.


Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

McCubrey J, Steelman L, Franklin R, Abrams S, Chappell W, Wong E Adv Enzyme Regul. 2007; 47:64-103.

PMID: 17382374 PMC: 2696319. DOI: 10.1016/j.advenzreg.2006.12.013.